Sat.Jun 01, 2024 - Fri.Jun 07, 2024

article thumbnail

Abbott’s OTC glucose monitor ‘will grow the market’

pharmaphorum

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its Lingo device - and analysts think uptake by patients is now poised to take off.

Marketing 115
article thumbnail

After 33 years, Geron finally crosses FDA finish line with blood cancer med Rytelo

Fierce Pharma

Once hailed as an anti-aging magic bullet, telomerase has failed to live up to the hype as it was profiled in a | The FDA has approved Geron Corporation's Rytelo (imetelstat) to treat a group of bone marrow disorders called myelodysplastic syndrome (MDS). The approval is the first for the 33-year-old California biotech.

FDA 338
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why the Cyberattack on Ascension Scared 5 Hospital Execs & How They’re Responding

MedCity News

As majorly disruptive cyberattacks continue to make headlines in the healthcare world, hospitals are prioritizing cybersecurity more than ever before. This piece explores reactions from five different health system executives about the recent attack on Ascension — as well as what they’re doing to prevent a similar fate at their own organization and how they want things to change going forward.

article thumbnail

7 Reasons To Choose The Medical Sales Field

David Bagga

Medical Device Sales Academy 7 Reasons To Choose The Medical Sales Field If you are considering a new career path or career change in the medical field, this post is for you. The blog could be what you’ve been looking for in Medical software sales. This exciting and profitable field pays well, is secure, and […] The post 7 Reasons To Choose The Medical Sales Field appeared first on.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

ASCO: Conversational AI tackles missed colonoscopies

pharmaphorum

An AI tool has shown impressive results in raising colorectal cancer screening rates in underserved populations, according to data presented at ASCO

126
126
article thumbnail

ASCO: AstraZeneca, Daiichi's Enhertu looks to make history again in HER2-ultralow breast cancer

Fierce Pharma

After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that the antibody-drug conjugate can reach tumors with an even lower express | After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that the antibody-drug conjugate can reach tumors with an even lower expression of the protein biomarker.

328
328

More Trending

article thumbnail

Regenerative cell therapy biotech uses IPO to blast into human trials

PharmaVoice

Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.

Marketing 119
article thumbnail

Mexican man dies in first human case of H5N2 bird flu

pharmaphorum

A man in Mexico has died in what the WHO has said is the first lab-confirmed human infection with the H5N2 strain of bird flu

122
122
article thumbnail

Lilly wins NICE endorsement for tirzepatide in obesity—with a catch

Fierce Pharma

A little less than a year after Eli Lilly won the blessing of England's drug value watchdog for tirzepatide in Type 2 diabetes, the National Institute for Health and Care Excellence (NICE) has retu | A little less than a year after Eli Lilly won the blessing of England's drug value watchdog for tirzepatide in Type 2 diabetes, the National Institute for Health and Care Excellence (NICE) has returned with an endorsement in obesity.

325
325
article thumbnail

SCOTUS Deals a Blow to Medical Debt Collectors

MedCity News

The Consumer Financial Protection Bureau, which has been targeting debt collection practices, survives a Supreme Court challenge. The post SCOTUS Deals a Blow to Medical Debt Collectors appeared first on MedCity News.

Medical 129
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Exploring the Potential of mRNA (BIO 2024)

PharmaTech

Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.

115
115
article thumbnail

ASCO: DREAMM-8 data puts GSK’s Blenrep back on track

pharmaphorum

GSK planning to refile anti-BCMA drug Blenrep in the US for multiple myeloma after reporting positive results from the DREAMM-8 trial at ASCO

119
119
article thumbnail

Bristol Myers puts more than 860 jobs on chopping block in NJ as $1.5B savings campaign rolls ahead

Fierce Pharma

The scope of Bristol Myers Squibb’s $1.5 billion savings drive is beginning to come into focus. | Starting this month, BMS will begin the process of laying off around 863 employees in Lawrenceville, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) alert from the state. The move forms part of BMS’ campaign to shave off $1.5 billion in costs by the end of 2025, a company spokesperson said over email.

321
321
article thumbnail

Gameto Secures $33M To Support Clinical Development of Fertility Treatment

MedCity News

Gameto’s $33 million Series B funding round was led by Two Sigma Ventures and RA Capital. The funding will help with the clinical development of its in vitro maturation product called Fertilo. The post Gameto Secures $33M To Support Clinical Development of Fertility Treatment appeared first on MedCity News.

Biopharma 127
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Regulation and legislation in the era of automation and digitalisation

European Pharmaceutical Review

Friend or foe? Pharmaceutical companies ask themselves this question before embracing the latest technologies because every innovation comes with both opportunities and risks. Today, technological advancements in artificial intelligence (AI), machine learning (ML), digitalisation, and robotic manufacturing automation solutions stand to revolutionise R&D, clinical trials, and manufacturing in the pharmaceutical industry.

article thumbnail

Buoyed by new obesity data, Structure files $476m offering

pharmaphorum

Riding high from positive clinical trial results for its oral weight-loss therapy, Structure Therapeutics has filed a public offering that it hopes will raise $476 million

118
118
article thumbnail

From one juggernaut to another: Lilly CFO Anat Ashkenazi takes same role at tech giant Alphabet

Fierce Pharma

After 23 years at Eli Lilly, including the last three as its CFO, Anat Ashkenazi is leaving to take the same role at Google's parent company Alphabet.

311
311
article thumbnail

Preventative Care: The Right Approach to Improving Endpoint Security

MedCity News

While firewalls, network monitoring and other security practices are imperative, it pays to give more thought to how to better secure endpoint computing. The post Preventative Care: The Right Approach to Improving Endpoint Security appeared first on MedCity News.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

NIH AI tool predicts cancer patients’ immunotherapy outcomes

Pharmaceutical Technology

Scientists at the NIH have introduced an AI tool to predict the response to immune checkpoint inhibitors for cancer patients.

Patients 112
article thumbnail

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

pharmaphorum

AstraZeneca's ASCO 'super sunday' delivers new data for Tagrisso and Imfinzi in lung cancer and Enhertu in breast cancer

117
117
article thumbnail

ASCO: AstraZeneca's Tagrisso, Imfinzi break new ground in lung cancer—with one standing ovation

Fierce Pharma

A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% improvement. | A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% and earned a standing ovation at ASCO 2024.

Patients 312
article thumbnail

At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer

MedCity News

AstraZeneca’s Tagrisso and Imfinzi helped patients live longer in separate pivotal clinical trials evaluating the drugs in two different types of lung cancer. The results will be presented Sunday during the annual meeting of the American Society of Clinical Oncology. The post At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer appeared first on MedCity News.

Patients 123
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

GLP-1 treatment displays best-in-class potential for MASH

European Pharmaceutical Review

New sub-analysis data from a Phase II clinical trial show that after 48 weeks of survodutide treatment, 83.0 percent of adults with liver fibrosis achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH). This is compared to 18.2 percent with placebo. With its novel mechanism of action, the glucagon/GLP-1 receptor dual agonist is the first to show this level of fibrosis benefit in a Phase II MASH trial following 48 weeks of treatment, according

Medicine 111
article thumbnail

First rare disease therapies chosen for FDA START programme

pharmaphorum

An initiative set up by the FDA to accelerate the development of therapies for rare disease in the same way that Operation Warp Speed delivered COVID-19 vaccine has chosen its first pilot programme candidates.

FDA 116
article thumbnail

Akeso, Summit's Keytruda win draws 'explosive' interest at ASCO. But what does Merck think?

Fierce Pharma

On the eve of the American Society of Clinical Oncology’s annual meeting last week, a piece of news set off vigorous discussions. | After Akeso and Summit's ivonescimab beat Keytruda in a head-to-head trial in non-small cell lung cancer, analysts are trying to sort out the financial ramifications while biopharma insiders are eager to see the exact data.

Biopharma 312
article thumbnail

Another Retailer Bites the Dust. Is There Still Hope for Retailers After Dollar General/DocGo End Pilot?

MedCity News

Dollar General and DocGo have mutually decided to end their mobile clinic pilot. The decision comes as numerous retailers have struggled in the healthcare sector. The post Another Retailer Bites the Dust. Is There Still Hope for Retailers After Dollar General/DocGo End Pilot? appeared first on MedCity News.

Retail 122
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

The Intersection of Chemistry, Robotics, and AI in Drug Discovery (BIO 2024)

PharmaTech

Lee Cronin, founder and CEO of Chemify, discusses the combination of digital chemistry, robotics, and AI in the drug discovery space.

110
110
article thumbnail

ASCO: KRAS upstarts set their sights on NSCLC market

pharmaphorum

KRAS inhibitors from Eli Lilly, Genfleet, and InxMed make their case for use in NSCLC at ASCO, as they case down Amgen and Bristol-Myers Squibb's market drugs

Marketing 116
article thumbnail

Lawmakers request intelligence briefing on CDMO GenScript, Legend Biotech's ties to China

Fierce Pharma

For several months, a U.S. security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party (CCP) has continued to gain steam. | For several months, a U.S. security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party has continued to gain steam. Now, several new names could be feeling the heat.

Biopharma 306
article thumbnail

How Testosterone is Revolutionizing Menopause Care

MedCity News

Shedding light on misconceptions about testosterone and women’s health The post How Testosterone is Revolutionizing Menopause Care appeared first on MedCity News.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time